Nieuws en video's - ALBIREO PHARMA INC.

Bylvay (odevixibat) granted Priority Review by U.S. FDA ASSERT study demonstrated efficacy of Bylvay in pruritus, bile acids and sleep with a low drug-related diarrhea rate in Alagille patients Approval in second indication would more than double Bylvay market opportunity BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced that the U.S. Food and...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Albireo Pharma, Inc. (NasdaqCM: ALBO) to Ipsen S.A. Under the terms of the proposed transaction, shareholders of Albireo will receive $42.00 in cash plus one contingent value right per share (CVR) (entitling its holder to deferred cash payments of $10.00 per CVR payable upon the U.S. Food and Drug Administration’s approval of Bylvay in...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Albireo Pharma, Inc. (NasdaqCM: ALBO) to Ipsen S.A. Under the terms of the proposed transaction, shareholders of Albireo will receive $42.00 in cash plus one contingent value right per share (CVR) (entitling its holder to deferred cash payments of $10.00 per CVR payable upon the U.S. Food and Drug Administration’s approval of Bylvay in...

SHAREHOLDER ALERT: Weiss Law Investigates Albireo Pharma, Inc. PR Newswire NEW YORK, Jan. 9, 2023 NEW YORK , Jan. 9, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Albireo Pharma, Inc. ("Albireo" or the "Company") (NASDAQ: ALBO), in connection with the proposed acquisition of the Company by Ipsen S.A. (OTC: IPSEY) via tender offer. Under the terms of the merger agreement, the Company's shareholders will...

ALERT: The M&A Class Action Firm Announces the Investigation of Albireo Pharma, Inc. - ALBO PR Newswire NEW YORK, Jan. 9, 2023 NEW YORK , Jan. 9, 2023 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City , is investigating Albireo Pharma,...

Shareholder Alert: Ademi LLP investigates whether Albireo Pharma, Inc. has obtained a Fair Price in its transaction with Ipsen PR Newswire MILWAUKEE, Jan. 9, 2023 MILWAUKEE , Jan. 9, 2023 /PRNewswire/ -- Ademi LLP is investigating Albireo (Nasdaq: ALBO) for possible breaches of fiduciary duty and other violations of law in its transaction with Ipsen. Click here to learn how to join the action https://www.ademilaw.com/case/albireo-pharma-inc or call Guri Ademi toll-free at 866-264-3995. There is...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Albireo Pharma, Inc. (NASDAQ: ALBO) to Ipsen is fair to Albireo shareholders. Per the terms of the proposed transaction, Ipsen would acquire Albireo for $42.00 per share in cash plus one contingent value right per share (CVR), entitling its holder to deferred cash payments of $10.00 per CVR payable upon the U.S. Food and Drug Administration’s approval of Bylvay in the Biliary Atresia indication by December 31,...

BOSTON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced the grant to its newly appointed Chief Medical Officer, Paul D. Streck, M.D., of inducement restricted stock units to acquire 63,966 shares of Albireo’s common stock. The restricted stock units were granted as an inducement material to Dr. Streck’s acceptance of employment with Albireo in...

- Gold standard Phase 3 ASSERT study supports supplementary filings in the U.S. and EU - ASSERT study demonstrated efficacy of Bylvay (odevixibat) in pruritus, bile acids and sleep with a low drug-related diarrhea rate - Data submitted to support use across wide age range of patients, including those with JAG1 and NOTCH2 mutations BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and...

BOSTON, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced the grant of inducement restricted stock units to acquire 13,700 shares of Albireo’s common stock. The restricted stock units were granted as an inducement material to the employee’s acceptance of employment with Albireo in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted...

– Dr. Craig Hopkinson, currently EVP of Research & Development and Chief Medical Officer at Alkermes, brings strong global orphan drug development expertise – Dr. Paul Streck, former Chief Medical Officer at Arena Pharmaceuticals, brings significant global drug development and commercialization expertise – Two appointments strengthen Company’s ability to scale up global drug development and grow the portfolio BOSTON, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO),...

BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced that the Committee Economic Health Products (CEPS) has approved reimbursed access to Bylvay (odevixibat) in France following a favorable clinical assessment from the Haute Autorité de Santé (HAS) for the treatment of progressive familial intrahepatic cholestasis (PFIC) types 1 and 2 (except for...

BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in the Jefferies London Healthcare Conference in London, UK, from November 15-17, 2022. Simon Harford, Chief Financial Officer of Albireo, will be presenting on November 15, 2022, at 10:20 AM GMT. A replay of the webcast will be available on-demand on the Albireo Investors page:...

Bylvay ® (odevixibat) Q3 2022 PFIC net revenue of $7.5 million, September YTD 2022 $18.1 million New disease modification and native liver survival data with Bylvay in PFIC patients presented at AASLD Positive Bylvay Phase 3 ASSERT topline data in ALGS presented at AASLD; submissions on track Completed enrollment in BOLD study in biliary atresia, third Bylvay Phase 3 program Company to host a conference call and webcast today at 4:30 p.m. ET BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Albireo...

Early, rapid, and sustained efficacy across wide range of patients with evidence of disease modification Long-term preservation of native liver in PFIC, improvements in pruritus, bile acids, and increased growth over time Late-breaking oral presentation demonstrates restoration of bile acid secretion in PFIC patients receives “Best of Liver Meeting” distinction Late-breaking oral presentation of new positive Phase 3 ASSERT trial results in Alagille syndrome receives “Best of Liver...

— Eight projects selected for inaugural year of the program — Projects provide solutions to make a tangible difference in the lives of PFIC patients BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced the winners of the Supporting PFIC Advances Research and Knowledge (SPARK) grants program, established by Albireo to identify and drive forward...

– BOLD is the first, largest, and only global Phase 3 trial designed to meet regulatory agencies' requirements – On track to report topline data by the end of 2024, reinforcing Bylvay's expected position as first IBAT inhibitor to market in biliary atresia BOSTON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced the completion of patient enrollment...

– Oral late breaker with new results from positive Phase 3 ASSERT study in Alagille syndrome (ALGS) – Oral late breaker provides evidence of disease modification in PFIC – Analysis of PEDFIC 1 data showed restoration of bile acid secretion in patients with PFIC2 BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced the acceptance of two late...

BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 4:30 p.m. ET on November 8, 2022, to provide a business update and review the company’s financial results for the quarter ended September 30, 2022. To access the live conference call by phone, dial 1-855-327-6837 (domestic) or 1-631-891-4304 (international), and...

Hochgradige statistisch signifikante Linderung von Juckreiz, dem primären Endpunkt (p=0,002) Signifikante Verringerung des Gallensäurespiegels im Serum, dem wichtigsten sekundären Endpunkt (p=0,001) Erhebliche Verbesserungen bei multiplen Schlafparametern Gute Verträglichkeit mit geringem Auftreten arzneimittelbedingter Diarrhö, keine Abbrüche Geplante sofortige Einreichung eines Antrags in den USA und in der EU und Erweiterung der genehmigten Indikation für PFIC BOSTON, Oct. 19, 2022...